PHASE 1 DOSE-ESCALATING STUDY OF BMS-754807 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Tamura, Y. [1 ]
Nokihara, H. [1 ]
Yamamoto, N. [1 ]
Wakui, H. [1 ]
Honda, K. [1 ]
Asahina, H. [1 ]
Yamada, Y. [1 ]
Komaba, T. [2 ]
Tamura, T. [1 ]
机构：
[1] Natl Canc Ctr Hosp, Dept Internal Med, Kashiwa, Chiba, Japan
[2] Bristol Myers KK, Bristol, Avon, England
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [1] Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
    Sachi Morita
    Satoshi Oizumi
    Hironobu Minami
    Koichi Kitagawa
    Yoshito Komatsu
    Yutaka Fujiwara
    Megumi Inada
    Satoshi Yuki
    Naomi Kiyota
    Ayako Mitsuma
    Masataka Sawaki
    Hiromi Tanii
    Junko Kimura
    Yuichi Ando
    Investigational New Drugs, 2012, 30 : 1950 - 1957
  • [2] Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
    Morita, Sachi
    Oizumi, Satoshi
    Minami, Hironobu
    Kitagawa, Koichi
    Komatsu, Yoshito
    Fujiwara, Yutaka
    Inada, Megumi
    Yuki, Satoshi
    Kiyota, Naomi
    Mitsuma, Ayako
    Sawaki, Masataka
    Tanii, Hiromi
    Kimura, Junko
    Ando, Yuichi
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 1950 - 1957
  • [3] A phase IA, dose-escalating study of LBH589 administered intravenously in adult patients with advanced solid tumors
    Oizumi, S.
    Ando, Y.
    Kitagawa, K.
    Morita, S.
    Komatsu, Y.
    Yuki, S.
    Fujiwara, Y.
    Kiyota, N.
    Kobayashi, K.
    Minami, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 124 - 125
  • [4] Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors
    Yuan, Yuan
    Cohen, Deirdre J.
    Love, Erica
    Yaw, Michelle
    Levinson, Benjamin
    Nicol, Steven J.
    Hochster, Howard S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 371 - 378
  • [5] Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors
    Yuan Yuan
    Deirdre J. Cohen
    Erica Love
    Michelle Yaw
    Benjamin Levinson
    Steven J. Nicol
    Howard S. Hochster
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 371 - 378
  • [6] Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
    Naing, Aung
    Fu, Siqing
    Zinner, Ralph G.
    Wheler, Jennifer J.
    Hong, David S.
    Arakawa, Kazuhito
    Falchook, Gerald S.
    Kurzrock, Razelle
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 154 - 159
  • [7] Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
    Aung Naing
    Siqing Fu
    Ralph G. Zinner
    Jennifer J. Wheler
    David S. Hong
    Kazuhito Arakawa
    Gerald S. Falchook
    Razelle Kurzrock
    Investigational New Drugs, 2014, 32 : 154 - 159
  • [8] Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors
    Desai, J.
    Solomon, B. J.
    Davis, I. D.
    Lipton, L. R.
    Hicks, R.
    Scott, A. M.
    Park, J.
    Clemens, P. L.
    Gestone, T. A.
    Finckenstein, F. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Vilar, Eduardo
    Gruenwald, Viktor
    Schoeffski, Patrick
    Singer, Harald
    Salazar, Ramon
    Luis Iglesias, Jose
    Casado, Esther
    Cullell-Young, Martin
    Baselga, Jose
    Tabernero, Josep
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 299 - 305
  • [10] A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Hirata, Taizo
    Goto, Yasushi
    Tanioka, Maki
    Ikeda, Yoko
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 559 - 565
12345